These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28276705)

  • 21. The impact of epigenomics on future drug design and new therapies.
    Hamm CA; Costa FF
    Drug Discov Today; 2011 Jul; 16(13-14):626-35. PubMed ID: 21570477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery.
    Speck-Planche A; Cordeiro MN
    Expert Opin Drug Discov; 2015 Mar; 10(3):245-56. PubMed ID: 25613725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic approaches for bipolar disorder drug discovery.
    Peedicayil J
    Expert Opin Drug Discov; 2014 Aug; 9(8):917-30. PubMed ID: 24875048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery.
    Naveja JJ; Medina-Franco JL
    Expert Opin Drug Discov; 2015 Oct; 10(10):1059-70. PubMed ID: 26289576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QSAR studies in the discovery of novel type-II diabetic therapies.
    Abuhammad A; Taha MO
    Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle".
    Dzobo K
    OMICS; 2019 Feb; 23(2):70-85. PubMed ID: 30767728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and opportunities in epigenetic drug discovery.
    Cummings RT; Maegley K; Hill WA; Sims R; Mohin S
    Assay Drug Dev Technol; 2014 Oct; 12(8):452-6. PubMed ID: 25127183
    [No Abstract]   [Full Text] [Related]  

  • 29. Applications of chemogenomic library screening in drug discovery.
    Jones LH; Bunnage ME
    Nat Rev Drug Discov; 2017 Apr; 16(4):285-296. PubMed ID: 28104905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs and Epigenetic Molecular Functions. A Pharmacological Data Scientometric Analysis.
    Kringel D; Malkusch S; Lötsch J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective targeting of epigenetic reader domains.
    Greschik H; Schüle R; Günther T
    Expert Opin Drug Discov; 2017 May; 12(5):449-463. PubMed ID: 28277835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoepigenetics: an element of personalized therapy?
    Majchrzak-Celińska A; Baer-Dubowska W
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):387-398. PubMed ID: 27860490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using quantitative systems pharmacology for novel drug discovery.
    Pérez-Nueno VI
    Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic multiple modulators.
    Álvarez R; Altucci L; Gronemeyer H; de Lera AR
    Curr Top Med Chem; 2011 Nov; 11(22):2749-87. PubMed ID: 22039877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.
    Andreoli F; Barbosa AJ; Parenti MD; Del Rio A
    Curr Pharm Des; 2013; 19(4):578-613. PubMed ID: 23016851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors.
    Liu Z; Gao Y; Li X
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):139-149. PubMed ID: 30470148
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting intrinsically disordered proteins in rational drug discovery.
    Ambadipudi S; Zweckstetter M
    Expert Opin Drug Discov; 2016; 11(1):65-77. PubMed ID: 26549326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Providing data science support for systems pharmacology and its implications to drug discovery.
    Hart T; Xie L
    Expert Opin Drug Discov; 2016; 11(3):241-56. PubMed ID: 26689499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico drug repositioning: what we need to know.
    Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
    Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.